ESC 365 - Doctor Arthur Mader

Speaker illustration

Doctor Arthur Mader

VIVIT Institute, Feldkirch (Austria)

Member of:

Heart Failure Association

Three decades of lipid-lowering therapy in type 2 diabetic patients with angiographically proven stable coronary artery disease

Event: ESC Congress 2024

Topic: Pharmacotherapy

Session: Medical and percutaneous treatment of coronary artery disease

Cystatin C predicts cardiovascular events in patients with coronary artery disease both among patients with and among those without type 2 diabetes

Event: ESC Congress 2024

Topic: Biomarkers

Session: Novel biomarkers for cardiovascular risk prediction

Remnant cholesterol predicts major cardiovascular events in coronary artery disease patients with NAFLD

Event: ESC Congress 2024

Topic: Lipids

Session: Lipoproteins and cardiovascular risk

The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes

Event: ESC Congress 2019

Topic: Biomarkers

Session: Diabetes and the heart

Serum ceramides and type 2 diabetes are mutually independent predictors of cardiovascular events in patients with peripheral artery disease

Event: ESC Congress 2019

Topic: Biomarkers

Session: Vascular disease

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources